Unraveling binding mechanism and kinetics of macrocyclic Gα protein inhibitors.

Jan H Voss, Jessica Nagel, Muhammad Rafehi, Ramon Guixà-González, Davide Malfacini, Julian Patt, Stefan Kehraus, Asuka Inoue, Gabriele M König, Evi Kostenis, Xavier Deupi, Vigneshwaran Namasivayam, Christa E Müller

Journal: Pharmacological research 2022;173():105880

PMID: 34506902

Abstract

G proteins represent intracellular switches that transduce signals relayed from G protein-coupled receptors. The structurally related macrocyclic depsipeptides FR900359 (FR) and YM-254890 (YM) are potent, selective inhibitors of the Gα protein family. We recently discovered that radiolabeled FR and YM display strongly divergent residence times, which translates into significantly longer antiasthmatic effects of FR. The present study is aimed at investigating the molecular basis for this observed disparity. Based on docking studies, we mutated amino acid residues of the Gα protein predicted to interact with FR or YM, and recombinantly expressed the mutated Gα proteins in cells in which the native Gα proteins had been knocked out by CRISPR-Cas9. Both radioligands showed similar association kinetics, and their binding followed a conformational selection mechanism, which was rationalized by molecular dynamics simulation studies. Several mutations of amino acid residues near the putative binding site of the "lipophilic anchors" of FR, especially those predicted to interact with the isopropyl group present in FR but not in YM, led to dramatically accelerated dissociation kinetics. Our data indicate that the long residence time of FR depends on lipophilic interactions within its binding site. The observed structure-kinetic relationships point to a complex binding mechanism of FR, which likely involves snap-lock- or dowel-like conformational changes of either ligand or protein, or both. These experimental data will be useful for the design of compounds with a desired residence time, a parameter that has now been recognized to be of utmost importance in drug development.

Copyright © 2021. Published by Elsevier Ltd.

Address: PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.; Condensed Matter Theory Group, Paul Scherrer Institute (PSI), Forschungsstrasse 111, Villigen 5232, Switzerland.; Institute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53113 Bonn, Germany.; Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Miyagi 980-8578 Japan.; Condensed Matter Theory Group, Paul Scherrer Institute (PSI), Forschungsstrasse 111, Villigen 5232, Switzerland; Laboratory of Biomolecular Research, Paul Scherrer Institute (PSI), Forschungsstrasse 111, Villigen 5232, Switzerland.; PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.